Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on developing gene therapy solutions for common eye diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's presentation is scheduled for Tuesday, February 11, at 4:40 p.m. ET.
Interested parties can access the presentation webcast through the Events and Presentations section in the Investors area of Adverum's website. The presentation recording will remain available for viewing on the company's website for a minimum of 30 days after the event.
Adverum Biotechnologies (Nasdaq: ADVM), una compagnia in fase clinica impegnata nello sviluppo di soluzioni di terapia genica per le malattie oculari comuni, ha annunciato la sua prossima partecipazione alla 35ª Conferenza Annuale Oppenheimer sulle Scienze della Vita e della Salute. La presentazione dell'azienda è programmata per martedì 11 febbraio, alle 16:40 ora orientale.
Le parti interessate possono accedere al webcast della presentazione attraverso la sezione Eventi e Presentazioni nell'area Investitori del sito web di Adverum. La registrazione della presentazione rimarrà disponibile per la visione sul sito dell'azienda per un minimo di 30 giorni dopo l'evento.
Adverum Biotechnologies (Nasdaq: ADVM), una empresa en etapa clínica centrada en el desarrollo de soluciones de terapia génica para enfermedades oculares comunes, ha anunciado su próxima participación en la 35ª Conferencia Anual de Ciencias de la Salud Oppenheimer. La presentación de la empresa está programada para el martes 11 de febrero, a las 4:40 p.m. ET.
Las partes interesadas pueden acceder a la transmisión en vivo de la presentación a través de la sección de Eventos y Presentaciones en el área de Inversores del sitio web de Adverum. La grabación de la presentación estará disponible para ver en el sitio web de la empresa durante un mínimo de 30 días después del evento.
Adverum Biotechnologies (Nasdaq: ADVM)는 일반적인 안 질환에 대한 유전자 치료 솔루션 개발에 집중하는 임상 단계의 회사로, 오펜하이머 제35회 연례 헬스케어 생명과학 회의에 참석할 예정이라고 발표했습니다. 회사의 발표는 2월 11일 화요일 오후 4시 40분 동부 표준시로 예정되어 있습니다.
관심 있는 분들은 Adverum 웹사이트의 투자자 구역에 있는 이벤트 및 발표 섹션을 통해 발표 웹캐스트에 접근할 수 있습니다. 발표 녹음은 행사 후 최소 30일 동안 회사 웹사이트에서 시청할 수 있습니다.
Adverum Biotechnologies (Nasdaq: ADVM), une entreprise en phase clinique axée sur le développement de solutions de thérapie génique pour les maladies oculaires courantes, a annoncé sa prochaine participation à la 35e Conférence Annuelle Oppenheimer sur la Santé et les Sciences de la Vie. La présentation de l'entreprise est prévue pour mardi 11 février à 16h40, heure de l'Est.
Les parties intéressées peuvent accéder au webinaire de la présentation via la section Événements et Présentations dans la zone Investisseurs du site Web d'Adverum. L'enregistrement de la présentation restera disponible sur le site de l'entreprise pendant au moins 30 jours après l'événement.
Adverum Biotechnologies (Nasdaq: ADVM), ein klinisch aktives Unternehmen, das sich auf die Entwicklung von Gentherapielösungen für häufige Augenerkrankungen konzentriert, hat seine bevorstehende Teilnahme an der 35. jährlichen Oppenheimer-Konferenz über Gesundheits- und Lebenswissenschaften bekannt gegeben. Die Präsentation des Unternehmens ist für Dienstag, den 11. Februar, um 16:40 Uhr ET angesetzt.
Interessierte Parteien können über den Bereich Veranstaltungen und Präsentationen im Investorenspezialbereich der Adverum-Website auf den Webcast der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird auf der Unternehmenswebsite mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, at 4:40 p.m. ET.
The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the event.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
When is Adverum Biotechnologies (ADVM) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Adverum's (ADVM) Oppenheimer Conference presentation?
How long will Adverum's (ADVM) Oppenheimer Conference presentation be available for replay?
What is Adverum Biotechnologies' (ADVM) current focus in gene therapy?
